Part 9/12:
A significant factor contributing to these high costs is the lack of negotiation power for the US government with pharmaceutical companies, a situation exacerbated by policies like the Medicare Noninterference clause. Additionally, the hidden and unethical relationships between healthcare providers and pharma companies introduce conflicts of interest, as pharmaceutical payments to doctors have skyrocketed, raising questions about the integrity of prescriptions and treatment recommendations.